Stock & Company Details
DaVita Inc $DVA
Price:
N/A
N/A
64M
$11B
52 Week High:
N/A
10 Day Average Volume:
N/A
14.50
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Services
DVA technical indicators
Latest DaVita Inc (DVA) indicator readings as of 2026-10-09.
DVA's 14-day RSI is 47.0, in neutral territory. At $179.25 it is trading 4.4% above its 200-day moving average of $171.62, and below its 50-day average of $183.49. Price sits in the middle of its Bollinger Bands ($170.41 to $191.46). ADX reads 17.6, indicating a range-bound market rather than a trend.
DVA backtested strategy results
How 4 rule-based strategies performed on DaVita Inc (DVA) over recent history, last backtested 2026-10-10. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +88.4% | 58% | 12 | -21.1% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +63.1% | 36% | 25 | -40.7% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +52.8% | 47% | 30 | -40.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +50.4% | 73% | 26 | -45.2% |
Overview
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Finance Bot
Ask your questions
Start by typing a question below.
